Revance Therapeutics Provides Update On RT001 Clinical Program For The Lead Indication For Crow's Feet Lines

By: via Benzinga
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.